Government Updates

Alpha Tau Receives Breakthrough Device Designation from the FDA for Alpha DaRT™

Alpha Tau Receives Breakthrough Device Designation from the FDA for Alpha DaRT™

Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT,TM is pleased to announce that it has received a Breakthrough Device Designation for Alpha DaRT from the U.S. Food and Drug Administration (FDA).

Alpha Tau This designation applies to the treatment of Squamous Cell Carcinoma of the skin and oral cavity without curative standard of care.

“The FDA’s recognition of the Alpha DaRT as a Breakthrough Device is a tremendous milestone for the company, as we seek to bring our revolutionary technology to patients in need,” said Alpha Tau CEO Uzi Sofer. “This confirms our long-standing hopes and expectations for this product, and comes at the perfect time to accelerate our clinical trial program that is moving ahead rapidly now in the U.S.”

Alpha Tau Chief Medical Officer Dr. Robert Den added, “This achievement was the result of the dedication and hard work of the entire Alpha Tau team. While we are motivated by our mission to help every patient possible, it is exciting and gratifying to see external recognition of our vision of clinical excellence.”

Breakthrough Device is a category designed by the FDA to expedite the review process and to facilitate the clinical trial development of devices that treat life-threatening conditions. The designation is awarded when a device’s preliminary clinical data suggest it might be more effective than the current standard of care on clinically significant endpoints of efficacy, safety, or patient quality of life.  In addition, to speed access to essential new medical technologies, a Medicare coverage pathway called Medicare Coverage of Innovative Technology stands to provide FDA Breakthrough Devices with Medicare coverage for 4 years following FDA marketing authorization.

Alpha Tau submitted data to the FDA supporting this designation, including a pilot clinical study of Alpha DaRT treatment of SCC of the skin, head and neck, in which almost 80% of the lesions showed a complete response, and 100% demonstrated a partial or complete response, alongside a mild safety profile.

In preclinical studies using Alpha DaRT, a response was observed in all tested solid tumors, including pancreatic, lung, breast, and prostate tumor cells. These cancers and others will be investigated as part of the Alpha DaRT clinical trial program, which includes a skin cancer feasibility trial currently ongoing at Memorial Sloan Kettering Cancer Center in New York and other sites across the U.S.

About Alpha Tau Medical, Ltd.

Founded in 2016, Alpha Tau Medical Ltd, is an Israeli oncology therapeutics company that focuses on research, development, and commercialization of the Alpha DaRT™ technology for the treatment of solid tumors.

Alpha DaRT™(Diffusing Alpha-emitters Radiation Therapy) is an innovative technology that enables the highly potent and uniquely conformal alpha-irradiation of solid tumors. The treatment is delivered by intratumoral insertion of Radium-224, which allows for the release and diffusion of alpha-emitting radioisotopes, releasing alpha particles that can destroy the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT mainly affects the tumor, and can spare the healthy tissue around it.

This article is shared with Prittle Prattle News in the form of a Press Release.

By Reporter

Alpha Tau Receives Breakthrough Device Designation from the FDA for Alpha DaRT™

Media of the day

Skip to toolbar